Historical hum News Stories
Humana Plunges: $3.5B Star-Rating Shock Hits Stock
Humana shares plunged after the company disclosed a $3.5B Medicare Advantage Star Ratings headwind, conservative 2026 guidance, an exit from unprofitable counties and a CMS proposal that implied nearly flat MA payment rates — all amplifying pressure on HUM stock.
Humana Faces $3.5B Headwind; HUM Rebounds Star Cut
Humana (HUM) recently weathered a steep selloff after a CMS rate surprise and conservative 2026 guidance tied to a $3.5 billion Medicare Advantage Star Ratings shortfall. The company has taken concrete steps—county exits and benefit trims—while investors reacted with a multi-day rebound. Key near-term catalysts include CMS final 2027 rates and execution on CenterWell-driven cost and quality improvements.
Humana Slides on $3.5B Star-Ratings Hit
Humana reported conservative 2026 guidance after Q4 results, citing a $3.5 billion headwind from lower Medicare Advantage Star Ratings. Strong membership growth contrasts with margin pressure driven by lost bonus payments and a muted CMS reimbursement update, prompting operational cuts and a sharp drop in HUM shares.
Humana Falls After Medicare Advantage Rate Cut Now
Humana shares dropped sharply this week following a modest Medicare Advantage rate proposal and renewed risk-adjustment scrutiny. The 0.9% proposed rate increase for 2027 and related policy pressures are creating tangible margin risk for Humana, which is heavily exposed to Medicare Advantage enrollment.